National and Kapodistrian University of Athens
Προσδιορισμός του νευροληπτικού φαρμάκου κλοζαπίνη και του κύριου μεταβολίτη αυτής σε βιολογικά υγρά με φασματομετρία μάζας: εφαρμογές στην κλινική και δικαστική τοξικολογία
Abstract
dc:descriptionClozapine (CLZ) is classified as an atypical antipsychotic drug due to its complex pharmacologic properties and different effects that produce comparing to those exhibited by more typical antipsychotics. CLZ is efficacious for the treatment of patients with schizophrenia who fail to show an acceptable response to standard antipsychotic drugs. However, the usage of CLZ has been restricted as a consequence of its side effects such as agranulocytosis, seizures and sedation. CLZ is rapidly absorbed and, prior to excretion, extensively metabolised in two major metabolites, N-desmethylclozapine (norclozapine: NCLZ) and clozapine-N-oxide (CLZNO). CLZNO is present in low amounts in the plasma of patients receiving CLZ, conversely NCLZ is present in significant amounts and usually determined along with CLZ. Most patients respond sufficiently to dosages between 300 and 500 mg/day. If improvement has not occurred, the dosage can be gradually increased to 900 mg/day. It is suggested that therapeutic response is correlated with clozapine plasma levels between 350 and 600ng/mL. Although the precisely toxic range of clozapine is not known, its side effects are considered to be dose-related. Clozapine needs to be closely monitored when its concentration is higher than 600 ng/mL in plasma. On the other hand, despite indications that NCLZ does not possess any clinical outcome, a recent review, suggests that higher NCLZ/ CLZ ratios may be associated with greater symptom improvement. These findings propose that, the complex interaction between CLZ and NCLZ at receptor sites makes it necessary for a validated method able to monitor not only CLZ but also NCLZ in clinical trials as well as in overdose and forensic cases. The aim of this study was to develop and validate a GC/MS specific method for the determination of clozapine and norclozapine in human plasma covering all therapeutic and toxic levels. A sensitive and specific GC/MS method for the determination of clozapine (CLZ) and its major metabolite norclozapine (NCLZ), in plasma has been developed, optimized and validated. Specimen preparation includes solid–phase extraction of both analytes using Bond-Elut Certify cartridge and further derivatization with TFAA. Clozapine-d8 was used as internal standard for the determination of CLZ and NCLZ. Limits of detection were 0.45ng/mL for CLZ and 1.59ng/mL for NCLZ, while limits of quantification were 1.37ng/mL for CLZ and 4.8ng/mL for NCLZ, as calculated by the calibration curves. The calibration curves were linear up to 600ng/mL for CLZ and NCLZ. Absolute recovery ranged from 82.22% to 95.35% for both analytes. Intra- and interday accuracy was less than 7.13% and −12.52%, respectively, while intra- and interday precision was between 9.5% and 12.07%, respectively, for CLZ and NCLZ. The method covers all therapeutic range and proved suitable for the determination of CLZ and NCLZ not only in psychiatric patients but also in forensic cases with clozapine implication.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vardakou, I.
- Βαρδάκου, Ιωάννα
Subjects
dc:subject × 20- Προσδιορισμός κλοζαπίνης
- Προσδιορισμός νορκλοζαπίνης
- Αέρια χρωματογραφία - φασματομετρία μάζας
- Πλάσμα
- Επικύρωση
- Σχιζοφρένεια
- Παρακολούθηση επιπέδων
- Εφαρμογή σε ασθενείς
- Determination of clozapine
- Determination of norclozapine
- Gas chromatography-mass spectrometry
- Plasma
- Validation
- Schizophrenia
- Therapeutic drug monitoring
- Application in psychiatric patients
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27259